Amgen’s Melanoma Vaccine Shows Durable Response; Survival Still A Hurdle
This article was originally published in The Pink Sheet Daily
Executive Summary
The vaccine acquired from BioVex at high cost still needs to demonstrate overall survival in Phase III and prove value in an increasingly competitive market for melanoma treatments.
You may also be interested in...
Amgen’s Trebananib Meets First Phase III Goal In Ovarian Cancer
Amgen’s trebananib (AMG 386) meets progression-free survival endpoint in Phase III TRINOVA-1 recurrent ovarian cancer study, but higher dropout rate than expected needs explanation. Company also moves IL-17 inhibitor brodalumab into Phase III for psoriatic arthritis.
Amgen’s Trebananib Meets First Phase III Goal In Ovarian Cancer
Amgen’s trebananib (AMG 386) meets progression-free survival endpoint in Phase III TRINOVA-1 recurrent ovarian cancer study, but higher dropout rate than expected needs explanation. Company also moves IL-17 inhibitor brodalumab into Phase III for psoriatic arthritis.
Yervoy Approval Has Shifted Development Landscape For Melanoma
With Bristol-Myers Squibb Co.’s ipilimumab cleared and Roche/Daiichi Sankyo’s BRAF inhibitor vemurafenib (RG7204) on track for a filing and perhaps approval this year, companies developing other melanoma drugs face a more complicated, competitive path to market.